ClinicalTrials.gg
CompletedNCT05151744Updated Oct 16, 2025Results posted

A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema

A Phase 2 interventional study of Vamikibart and Ranibizumab in Diabetic Macular Edema, sponsored by Hoffmann-La Roche. Completed at 38 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-16.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
187
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Macular Edema by Hoffmann-La Roche — 1 open to participants now, 5 under way, 1 of them phase 3. Macular Edema · Hoffmann-La Roche.

Enrollment
19th of 25
187 · median 377
Started
2021
with 3 others
Phase 2
4 of 28
none open now
Registered
17th of 28
by date

Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 19th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2021, is one of 4 in phase 2, and was the 17th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 28 studies in Macular Edema by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Macular Edema by Hoffmann-La Roche, or all of them as a file.
02

Study summary

Study BP43464 is a phase II, multicenter, randomized, double-masked active comparator-controlled study designed to assess the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of vamikibart in combination with, anti-vascular endothelial growth factor (VEGF) inhibitor, ranibizumab compared with ranibizumab alone in participants with diabetic macular edema. Only one eye will be chosen as the study eye. The duration of the study will be 76 weeks.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of diabetes mellitus (Type 1 or Type 2)
  • Macular thickening secondary to diabetic macular edema (DME) involving the center of the macula
  • Decreased visual acuity attributable primarily to DME
  • Ability and willingness to provide written and to comply with the study protocol
  • Willingness to allow Aqueous Humor collection
  • For women of : agreement to remain abstinent or use at least one highly effective method that results in a failure rate of \<1% per year during the treatment period and for at least 12 weeks after the final dose of study treatment

Exclusion criteria

Exclusion Criteria:

  • (HbA1c) of greater than (>) 12%
  • Uncontrolled blood pressure, defined as a systolic value greater than (>)180 millimeters of mercury (mmHg) and/or a diastolic value >100 mmHg while a patient is at rest
  • Currently pregnant or breastfeeding, or intend to become pregnant during the study
  • Prior treatment with panretinal photocoagulation or macular laser to the study eye
  • Any intraocular or periocular treatment within the past 16 weeks prior to Day 1 to the study eye
  • Prior Iluvien or Retisert implants within 3 years prior to Day 1 to the study eye
  • Prior or concomitant treatment with anti-VEGF therapy within 8 weeks prior to Day 1 to the study eye; Vabysmo\^TM within 16 weeks prior to Day 1, prior Beovu® is not permitted
  • Prior administration of IVT brolucizumab (Beovu®): ever; vamikibart: \</=24 weeks prior to Day 1) in either eye
  • Any proliferative diabetic retinopathy
  • Active intraocular or periocular infection or active intraocular inflammation in the study eye
  • Any current or history of ocular disease other than DME that may confound assessment of the macula or affect central vision in the study eye
  • Any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than DME in the study eye
  • Other protocol-specified inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
187 participants (actual)

Study arms

  • Experimental
    Arm A: Vamikibart + Ranibizumab

    Participants will receive vamikibart, 1 milligram (mg) administered as intravitreal (IVT) injection in combination with ranibizumab, 0.5 mg IVT, on Day 1 and every fourth week (Q4W) up to Week 44, for a total of 12 injections, followed by an observational period up to Week 72.

    Drug: Vamikibart · Drug: Ranibizumab

  • Active comparator
    Arm B: Ranibizumab

    Participants will receive ranibizumab, 0.5 mg IVT, from Day 1 and Q4W in combination with sham up to Week 44, for a total of 12 injections, followed by an observational period up to Week 72.

    Drug: Ranibizumab · Other: Sham Procedure

Interventions

  • Vamikibart will be administered by IVT injection in the study eye.

    Also known as: RO7200220

  • Ranibizumab will be administered by IVT injection in the study eye.

    Also known as: Lucentis

  • OtherSham Procedure

    Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48 in Treatment-naïve Participants

    BCVA was measured via Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity (VA) examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a Mixed Model for Repeated Measurements (MMRM) model.

    Time frame: Baseline, Week 44 and Week 48

Secondary outcomes

  1. Number of Participants With Systemic and Ocular Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Systemic AEs include all non-ocular AEs.

    Time frame: Up to Week 72

  2. Change From Baseline in BCVA Averaged Over Week 44 and Week 48 in Previously Treated Participants

    BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.

    Time frame: Baseline, Week 44 and Week 48

  3. Change From Baseline in BCVA Averaged Over Week 44 and Week 48 in Overall ITT Population

    BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.

    Time frame: Baseline, Week 44 and Week 48

  4. Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Treatment-naïve Participants

    BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.

    Time frame: Baseline, Week 32 and Week 36

  5. Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Previously Treated Participants

    BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.

    Time frame: Baseline, Week 32 and Week 36

  6. Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Overall ITT Population

    BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.

    Time frame: Baseline, Week 32 and Week 36

  7. Change From Baseline in BCVA Averaged Over Week 20 and Week 24 in Treatment-naïve Participants

    BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.

    Time frame: Baseline, Week 20 and Week 24

  8. Change From Baseline in BCVA Averaged Over Week 20 and Week 24 in Previously Treated Participants

    BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.

    Time frame: Baseline, Week 20 and Week 24

  9. Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Overall ITT Population

    BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.

    Time frame: Baseline, Week 20 and Week 24

  10. Change From Baseline in BCVA Over Time in Overall ITT Population

    BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  11. Percentage of Participants Gaining ≥ 15, ≥ 10, ≥ 5, or ≥ 0 Letters in BCVA Over Time in Overall ITT Population

    BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores indicate improvement in VA. Percentages have been rounded off.

    Time frame: Up to Week 72

  12. Percentage of Participants Losing ≥ 15, ≥ 10, or ≥ 5 Letters in BCVA Over Time in Overall ITT Population

    BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores indicate improvement in VA. Percentages have been rounded off.

    Time frame: Up to Week 72

  13. Percentage of Participants With BCVA ≥ 69 Letters (20/40 Snellen Equivalent) Over Time

    BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. Higher scores indicate improvement in VA. Percentages have been rounded off.

    Time frame: Baseline, Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  14. Percentage of Participants With BCVA ≥ 84 Letters (20/20 Snellen Equivalent) Over Time

    BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. Higher scores indicate improvement in VA. Percentages have been rounded off.

    Time frame: Baseline, Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  15. Percentage of Participants With BCVA ≤ 38 Letters (20/200 Snellen Equivalent) Over Time

    BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. Higher scores indicate improvement in VA. Percentages have been rounded off.

    Time frame: Baseline, Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  16. Change From Baseline in Central Subfield Thickness (CST) Averaged Over Week 44 and Week 48 in Treatment-naïve Participants

    CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 millimetre (mm) central subfield. CST was measured using spectral domain optical coherence tomography (SD-OCT). Negative change from baseline values denotes improvement. This analysis used a MMRM model.

    Time frame: Baseline, Week 44 and Week 48

  17. Change From Baseline in CST Averaged Over Week 44 and Week 48 in Previously Treated Participants

    CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used a MMRM model.

    Time frame: Baseline, Week 44 and Week 48

  18. Change From Baseline in CST Averaged Over Week 44 and Week 48 in Overall ITT Population

    CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.

    Time frame: Baseline, Week 44 and Week 48

  19. Change From Baseline in CST Averaged Over Week 32 and Week 36 in Treatment-naïve Participants

    CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.

    Time frame: Baseline, Week 32 and Week 36

  20. Change From Baseline in CST Averaged Over Week 32 and Week 36 in Previously Treated Participants

    CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.

    Time frame: Baseline, Week 32 and Week 36

  21. Change From Baseline Averaged Over Week 32 and Week 36 in Overall ITT Population

    CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.

    Time frame: Baseline, Week 32 and Week 36

  22. Change From Baseline in CST Averaged Over Week 20 and Week 24 in Treatment-naïve Participants

    CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.

    Time frame: Baseline, Week 20 and Week 24

  23. Change From Baseline in CST Averaged Over Week 20 and Week 24 in Previously Treated Participants

    CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.

    Time frame: Baseline, Week 20 and Week 24

  24. Change From Baseline in CST Averaged Over Week 20 and Week 24 in Overall ITT Population

    CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.

    Time frame: Baseline, Week 20 and Week 24

  25. Change From Baseline in CST Over Time in Overall ITT Population

    CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  26. Percentage of Participants With Absence of DME Over Time in Overall ITT Population

    Absence of DME was defined as CST \< 325 μm for Spectralis SD-OCT, or \< 315 μm for Cirrus SD-OCT or Topcon SD-OCT. Percentages have been rounded off.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72

  27. Percentage of Participants With Absence of Intraretinal Fluid (IRF) Over Time in Overall ITT Population

    The absence of IRF in the study eye (defined as IRF absent or definite outside center subfield only) was assessed by the central reading center using SD-OCT. The percentage of participants with absence of IRF at foveal center are reported. Percentages have been rounded off.

    Time frame: Baseline, Weeks 4, 12, 24, 36, 48, and 72

  28. Percentage of Participants With Absence of Subretinal Fluid (SRF) Over Time in Overall ITT Population

    The absence of SRF in the study eye (defined as SRF absent or definite outside center subfield only) was assessed by the central reading center using SD-OCT. The percentage of participants with absence of SRF at the foveal center are reported. Percentages have been rounded off.

    Time frame: Baseline, Weeks 4, 12, 24, 36, 48, and 72

07

Results

Posted Oct 16, 2025

Participant flow

A total of 187 participants with diabetic macular edema (DME) took part in the study at 37 investigative sites across the United States, Argentina, Israel, South Korea, Poland, Canada, Spain, and the United Kingdom from 17 December 2021 to 1 October 2024.

Participant flow — Overall Study
MilestoneArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Started9394
Previously-treated intent-to-treat (itt) population3231
Treatment-naive itt population6163
Completed6481
Not completed2913
Withdrew: Adverse event62
Withdrew: Death12
Withdrew: Lack of efficacy11
Withdrew: Lost to follow-up22
Withdrew: Need for rescue treatment01
Withdrew: Non-compliance with study drug01
Withdrew: Reason not specified100
Withdrew: Physician decision21
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject63

Outcome measures

PrimaryChange From Baseline in Best Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48 in Treatment-naïve Participants

BCVA was measured via Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity (VA) examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a Mixed Model for Repeated Measurements (MMRM) model.

Time frame:
Baseline, Week 44 and Week 48
Reported as:
Mean · letters
Change From Baseline in Best Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48 in Treatment-naïve Participants
lettersArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Change From Baseline in Best Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48 in Treatment-naïve Participants12.8 ± 1.309.4 ± 1.25
Statistical analysis
  • Arm A: Vamikibart + Ranibizumab vs Arm B: Ranibizumab · MMRM · p = 0.0625 · Difference in adjusted means: 3.4 · 95% CI -0.2 to 7.0
SecondaryNumber of Participants With Systemic and Ocular Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Systemic AEs include all non-ocular AEs.

Time frame:
Up to Week 72
Reported as:
Count of participants · Participants
Number of Participants With Systemic and Ocular Adverse Events (AEs)
ParticipantsArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Systemic AEs5460
Ocular AEs in Study Eyes3328
Ocular AEs in Fellow Eyes2527
SecondaryChange From Baseline in BCVA Averaged Over Week 44 and Week 48 in Previously Treated Participants

BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.

Time frame:
Baseline, Week 44 and Week 48
Reported as:
Mean · letters
Change From Baseline in BCVA Averaged Over Week 44 and Week 48 in Previously Treated Participants
lettersArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Change From Baseline in BCVA Averaged Over Week 44 and Week 48 in Previously Treated Participants11.1 ± 1.508.4 ± 1.49
Statistical analysis
  • Arm A: Vamikibart + Ranibizumab vs Arm B: Ranibizumab · MMRM · p = 0.2052 · Difference in adjusted mean: 2.7 · 95% CI -1.5 to 7.0
SecondaryChange From Baseline in BCVA Averaged Over Week 44 and Week 48 in Overall ITT Population

BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.

Time frame:
Baseline, Week 44 and Week 48
Reported as:
Mean · letters
Change From Baseline in BCVA Averaged Over Week 44 and Week 48 in Overall ITT Population
lettersArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Change From Baseline in BCVA Averaged Over Week 44 and Week 48 in Overall ITT Population12.4 ± 0.999.1 ± 0.96
Statistical analysis
  • Arm A: Vamikibart + Ranibizumab vs Arm B: Ranibizumab · MMRM · p = 0.0192 · Difference in adjusted mean: 3.3 · 95% CI 0.5 to 6.0
SecondaryChange From Baseline in BCVA Averaged Over Week 32 and Week 36, in Treatment-naïve Participants

BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.

Time frame:
Baseline, Week 32 and Week 36
Reported as:
Mean · letters
Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Treatment-naïve Participants
lettersArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Treatment-naïve Participants11.8 ± 0.979.3 ± 0.94
Statistical analysis
  • Arm A: Vamikibart + Ranibizumab vs Arm B: Ranibizumab · MMRM · p = 0.0637 · Difference in adjusted mean: 2.5 · 95% CI -0.1 to 5.2
SecondaryChange From Baseline in BCVA Averaged Over Week 32 and Week 36, in Previously Treated Participants

BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.

Time frame:
Baseline, Week 32 and Week 36
Reported as:
Mean · letters
Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Previously Treated Participants
lettersArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Previously Treated Participants8.3 ± 1.437.5 ± 1.46
Statistical analysis
  • Arm A: Vamikibart + Ranibizumab vs Arm B: Ranibizumab · MMRM · p = 0.7091 · Difference in adjusted mean: 0.8 · 95% CI -3.3 to 4.9
SecondaryChange From Baseline in BCVA Averaged Over Week 32 and Week 36, in Overall ITT Population

BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.

Time frame:
Baseline, Week 32 and Week 36
Reported as:
Mean · letters
Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Overall ITT Population
lettersArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Overall ITT Population10.6 ± 0.818.7 ± 0.80
Statistical analysis
  • Arm A: Vamikibart + Ranibizumab vs Arm B: Ranibizumab · MMRM · p = 0.1107 · Difference in adjusted mean: 1.8 · 95% CI -0.4 to 4.1
SecondaryChange From Baseline in BCVA Averaged Over Week 20 and Week 24 in Treatment-naïve Participants

BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.

Time frame:
Baseline, Week 20 and Week 24
Reported as:
Mean · letters
Change From Baseline in BCVA Averaged Over Week 20 and Week 24 in Treatment-naïve Participants
lettersArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Change From Baseline in BCVA Averaged Over Week 20 and Week 24 in Treatment-naïve Participants10.6 ± 1.048.5 ± 1.01
Statistical analysis
  • Arm A: Vamikibart + Ranibizumab vs Arm B: Ranibizumab · MMRM · p = 0.1498 · Difference in adjusted mean: 2.1 · 95% CI -0.8 to 5.0
SecondaryChange From Baseline in BCVA Averaged Over Week 20 and Week 24 in Previously Treated Participants

BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.

Time frame:
Baseline, Week 20 and Week 24
Reported as:
Mean · letters
Change From Baseline in BCVA Averaged Over Week 20 and Week 24 in Previously Treated Participants
lettersArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Change From Baseline in BCVA Averaged Over Week 20 and Week 24 in Previously Treated Participants8.1 ± 1.466.2 ± 1.47
Statistical analysis
  • Arm A: Vamikibart + Ranibizumab vs Arm B: Ranibizumab · MMRM · p = 0.3783 · Difference in adjusted mean: 1.8 · 95% CI -2.3 to 6.0
SecondaryChange From Baseline in BCVA Averaged Over Week 20 and Week 24, in Overall ITT Population

BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.

Time frame:
Baseline, Week 20 and Week 24
Reported as:
Mean · letters
Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Overall ITT Population
lettersArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Overall ITT Population9.7 ± 0.847.8 ± 0.83
Statistical analysis
  • Arm A: Vamikibart + Ranibizumab vs Arm B: Ranibizumab · MMRM · p = 0.1036 · Difference in adjusted mean: 1.9 · 95% CI -0.4 to 4.3
SecondaryChange From Baseline in BCVA Over Time in Overall ITT Population

BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Mean · letters
Change From Baseline in BCVA Over Time in Overall ITT Population
lettersArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Baseline62.6 ± 1.0262.0 ± 1.01
Change at Week 46.7 ± 0.644.2 ± 0.65
Change at Week 87.6 ± 0.764.6 ± 0.76
Change at Week 128.9 ± 0.786.4 ± 0.78
Change at Week 169.3 ± 0.837.4 ± 0.83
Change at Week 209.7 ± 0.817.6 ± 0.80
Change at Week 249.8 ± 1.038.0 ± 1.02
Change at Week 2810.1 ± 0.878.5 ± 0.87
Change at Week 3210.5 ± 0.888.8 ± 0.87
Change at Week 3610.6 ± 0.848.6 ± 0.83
Change at Week 4010.9 ± 0.958.8 ± 0.93
Change at Week 4412.2 ± 1.018.7 ± 0.99
Change at Week 4812.5 ± 1.039.4 ± 1.00
Change at Week 5211.1 ± 1.078.0 ± 1.03
Change at Week 5610.8 ± 1.137.8 ± 1.09
Change at Week 6010.4 ± 1.187.7 ± 1.14
Change at Week 6410.2 ± 1.128.2 ± 1.10
Change at Week 689.9 ± 1.147.6 ± 1.11
Change at Week 729.2 ± 1.127.8 ± 1.11
SecondaryPercentage of Participants Gaining ≥ 15, ≥ 10, ≥ 5, or ≥ 0 Letters in BCVA Over Time in Overall ITT Population

BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores indicate improvement in VA. Percentages have been rounded off.

Time frame:
Up to Week 72
Reported as:
Number · percentage of participants
Percentage of Participants Gaining ≥ 15, ≥ 10, ≥ 5, or ≥ 0 Letters in BCVA Over Time in Overall ITT Population
percentage of participantsArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Participants Gaining ≥ 0 Letters98.998.9
Participants Gaining ≥ 5 Letters94.690.4
Participants Gaining ≥ 10 Letters76.369.1
Participants Gaining ≥ 15 Letters49.544.7
SecondaryPercentage of Participants Losing ≥ 15, ≥ 10, or ≥ 5 Letters in BCVA Over Time in Overall ITT Population

BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores indicate improvement in VA. Percentages have been rounded off.

Time frame:
Up to Week 72
Reported as:
Number · percentage of participants
Percentage of Participants Losing ≥ 15, ≥ 10, or ≥ 5 Letters in BCVA Over Time in Overall ITT Population
percentage of participantsArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Participants Losing ≥ 5 Letters19.427.7
Participants Losing ≥ 10 Letters7.511.7
Participants Losing ≥ 15 Letters4.36.4
SecondaryPercentage of Participants With BCVA ≥ 69 Letters (20/40 Snellen Equivalent) Over Time

BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. Higher scores indicate improvement in VA. Percentages have been rounded off.

Time frame:
Baseline, Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · percentage of participants
Percentage of Participants With BCVA ≥ 69 Letters (20/40 Snellen Equivalent) Over Time
percentage of participantsArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Baseline34.431.9
Week 153.448.9
Week 463.053.3
Week 867.048.9
Week 1273.056.5
Week 1669.757.5
Week 2074.767.0
Week 2470.661.6
Week 2871.863.2
Week 3278.862.5
Week 3672.662.7
Week 4078.470.6
Week 4482.167.1
Week 4880.970.4
Week 5278.664.2
Week 5682.158.7
Week 6082.068.8
Week 6482.569.8
Week 6881.171.4
Week 7282.771.1
SecondaryPercentage of Participants With BCVA ≥ 84 Letters (20/20 Snellen Equivalent) Over Time

BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. Higher scores indicate improvement in VA. Percentages have been rounded off.

Time frame:
Baseline, Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · percentage of participants
Percentage of Participants With BCVA ≥ 84 Letters (20/20 Snellen Equivalent) Over Time
percentage of participantsArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Baseline00
Week 12.30
Week 46.52.2
Week 810.25.6
Week 1210.18.7
Week 1613.56.9
Week 2014.58.8
Week 2417.68.1
Week 2812.911.5
Week 3217.513.8
Week 3613.712.0
Week 4012.211.8
Week 4423.98.9
Week 4823.514.8
Week 5215.77.4
Week 5614.99.3
Week 6013.19.4
Week 6419.311.3
Week 6818.910.2
Week 7211.511.1
SecondaryPercentage of Participants With BCVA ≤ 38 Letters (20/200 Snellen Equivalent) Over Time

BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. Higher scores indicate improvement in VA. Percentages have been rounded off.

Time frame:
Baseline, Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · percentage of participants
Percentage of Participants With BCVA ≤ 38 Letters (20/200 Snellen Equivalent) Over Time
percentage of participantsArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Baseline3.24.3
Week 12.32.2
Week 42.23.3
Week 82.33.3
Week 122.22.2
Week 161.11.1
Week 201.22.2
Week 242.41.2
Week 283.52.3
Week 322.51.3
Week 361.41.2
Week 402.72.4
Week 441.51.3
Week 4801.2
Week 521.40
Week 563.00
Week 601.61.6
Week 641.80
Week 681.90
Week 7200
SecondaryChange From Baseline in Central Subfield Thickness (CST) Averaged Over Week 44 and Week 48 in Treatment-naïve Participants

CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 millimetre (mm) central subfield. CST was measured using spectral domain optical coherence tomography (SD-OCT). Negative change from baseline values denotes improvement. This analysis used a MMRM model.

Time frame:
Baseline, Week 44 and Week 48
Reported as:
Mean · μm
Change From Baseline in Central Subfield Thickness (CST) Averaged Over Week 44 and Week 48 in Treatment-naïve Participants
μmArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Change From Baseline in Central Subfield Thickness (CST) Averaged Over Week 44 and Week 48 in Treatment-naïve Participants-202.4 ± 10.63-192.4 ± 10.11
Statistical analysis
  • Arm A: Vamikibart + Ranibizumab vs Arm B: Ranibizumab · MMRM · p = 0.4968 · Difference in adjusted mean: -10.0 · 95% CI -38.9 to 18.9
SecondaryChange From Baseline in CST Averaged Over Week 44 and Week 48 in Previously Treated Participants

CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used a MMRM model.

Time frame:
Baseline, Week 44 and Week 48
Reported as:
Mean · micrometre (μm)
Change From Baseline in CST Averaged Over Week 44 and Week 48 in Previously Treated Participants
micrometre (μm)Arm A: Vamikibart + RanibizumabArm B: Ranibizumab
Change From Baseline in CST Averaged Over Week 44 and Week 48 in Previously Treated Participants-194.4 ± 19.58-171.2 ± 18.79
Statistical analysis
  • Arm A: Vamikibart + Ranibizumab vs Arm B: Ranibizumab · MMRM · p = 0.3951 · Difference in adjusted mean: -23.2 · 95% CI -76.8 to 30.5
SecondaryChange From Baseline in CST Averaged Over Week 44 and Week 48 in Overall ITT Population

CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.

Time frame:
Baseline, Week 44 and Week 48
Reported as:
Mean · μm
Change From Baseline in CST Averaged Over Week 44 and Week 48 in Overall ITT Population
μmArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Change From Baseline in CST Averaged Over Week 44 and Week 48 in Overall ITT Population-201.6 ± 8.33-178.8 ± 8.15
Statistical analysis
  • Arm A: Vamikibart + Ranibizumab vs Arm B: Ranibizumab · MMRM · p = 0.0521 · Difference in adjusted mean: -22.8 · 95% CI -45.8 to 0.2
SecondaryChange From Baseline in CST Averaged Over Week 32 and Week 36 in Treatment-naïve Participants

CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.

Time frame:
Baseline, Week 32 and Week 36
Reported as:
Mean · μm
Change From Baseline in CST Averaged Over Week 32 and Week 36 in Treatment-naïve Participants
μmArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Change From Baseline in CST Averaged Over Week 32 and Week 36 in Treatment-naïve Participants-197.9 ± 10.26-180.3 ± 9.97
Statistical analysis
  • Arm A: Vamikibart + Ranibizumab vs Arm B: Ranibizumab · MMRM · p = 0.2227 · Difference in adjusted mean: -17.5 · 95% CI -45.7 to 10.7
SecondaryChange From Baseline in CST Averaged Over Week 32 and Week 36 in Previously Treated Participants

CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.

Time frame:
Baseline, Week 32 and Week 36
Reported as:
Mean · μm
Change From Baseline in CST Averaged Over Week 32 and Week 36 in Previously Treated Participants
μmArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Change From Baseline in CST Averaged Over Week 32 and Week 36 in Previously Treated Participants-177.2 ± 18.38-150.0 ± 18.38
Statistical analysis
  • Arm A: Vamikibart + Ranibizumab vs Arm B: Ranibizumab · MMRM · p = 0.2972 · Difference in adjusted mean: -27.2 · 95% CI -78.6 to 24.2
SecondaryChange From Baseline Averaged Over Week 32 and Week 36 in Overall ITT Population

CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.

Time frame:
Baseline, Week 32 and Week 36
Reported as:
Mean · μm
Change From Baseline Averaged Over Week 32 and Week 36 in Overall ITT Population
μmArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Change From Baseline Averaged Over Week 32 and Week 36 in Overall ITT Population-191.4 ± 8.51-172.1 ± 8.38
Statistical analysis
  • Arm A: Vamikibart + Ranibizumab vs Arm B: Ranibizumab · MMRM · p = 0.1071 · Difference in adjusted mean: -19.4 · 95% CI -42.9 to 4.2
SecondaryChange From Baseline in CST Averaged Over Week 20 and Week 24 in Treatment-naïve Participants

CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.

Time frame:
Baseline, Week 20 and Week 24
Reported as:
Mean · μm
Change From Baseline in CST Averaged Over Week 20 and Week 24 in Treatment-naïve Participants
μmArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Change From Baseline in CST Averaged Over Week 20 and Week 24 in Treatment-naïve Participants-184.3 ± 10.05-169.7 ± 9.89
Statistical analysis
  • Arm A: Vamikibart + Ranibizumab vs Arm B: Ranibizumab · MMRM · p = 0.3030 · Difference in adjusted mean: -14.6 · 95% CI -42.4 to 13.2
SecondaryChange From Baseline in CST Averaged Over Week 20 and Week 24 in Previously Treated Participants

CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.

Time frame:
Baseline, Week 20 and Week 24
Reported as:
Mean · μm
Change From Baseline in CST Averaged Over Week 20 and Week 24 in Previously Treated Participants
μmArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Change From Baseline in CST Averaged Over Week 20 and Week 24 in Previously Treated Participants-163.2 ± 17.75-120.2 ± 17.65
Statistical analysis
  • Arm A: Vamikibart + Ranibizumab vs Arm B: Ranibizumab · MMRM · p = 0.0878 · Difference in adjusted mean: -43.0 · 95% CI -92.4 to 6.4
SecondaryChange From Baseline in CST Averaged Over Week 20 and Week 24 in Overall ITT Population

CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.

Time frame:
Baseline, Week 20 and Week 24
Reported as:
Mean · μm
Change From Baseline in CST Averaged Over Week 20 and Week 24 in Overall ITT Population
μmArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Change From Baseline in CST Averaged Over Week 20 and Week 24 in Overall ITT Population-176.1 ± 9.89-153.9 ± 9.80
Statistical analysis
  • Arm A: Vamikibart + Ranibizumab vs Arm B: Ranibizumab · MMRM · p = 0.1111 · Difference in adjusted mean: -22.3 · 95% CI -49.8 to 5.2
SecondaryChange From Baseline in CST Over Time in Overall ITT Population

CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Mean · μm
Change From Baseline in CST Over Time in Overall ITT Population
μmArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Baseline493.0 ± 11.55498.4 ± 14.10
Change at Week 4-121.0 ± 9.82-92.2 ± 9.77
Change at Week 8-138.9 ± 9.67-108.2 ± 9.59
Change at Week 12-147.9 ± 9.63-125.3 ± 9.54
Change at Week 16-158.6 ± 10.28-138.3 ± 10.19
Change at Week 20-172.8 ± 10.11-149.8 ± 10.00
Change at Week 24-174.1 ± 10.12-152.9 ± 10.02
Change at Week 28-181.1 ± 10.53-154.1 ± 10.38
Change at Week 32-186.4 ± 8.87-165.6 ± 8.77
Change at Week 36-191.1 ± 9.58-174.9 ± 9.33
Change at Week 40-193.4 ± 8.92-166.7 ± 8.76
Change at Week 44-197.3 ± 8.95-172.7 ± 8.73
Change at Week 48-200.1 ± 9.04-179.2 ± 8.84
Change at Week 52-172.7 ± 12.92-136.9 ± 12.25
Change at Week 56-173.8 ± 11.43-129.2 ± 10.99
Change at Week 60-155.5 ± 13.18-130.6 ± 12.65
Change at Week 64-161.4 ± 13.65-163.0 ± 13.44
Change at Week 68-160.1 ± 11.26-136.6 ± 10.96
Change at Week 72-159.5 ± 11.62-154.3 ± 11.55
SecondaryPercentage of Participants With Absence of DME Over Time in Overall ITT Population

Absence of DME was defined as CST \< 325 μm for Spectralis SD-OCT, or \< 315 μm for Cirrus SD-OCT or Topcon SD-OCT. Percentages have been rounded off.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Reported as:
Number · percentage of participants
Percentage of Participants With Absence of DME Over Time in Overall ITT Population
percentage of participantsArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Baseline0 (NA to NA)2.1 (0.0 to 5.0)
Week 431.1 (21.5 to 40.7)25.8 (16.7 to 34.9)
Week 845.3 (34.8 to 55.9)37.8 (27.8 to 47.8)
Week 1247.1 (36.6 to 57.6)46.2 (35.9 to 56.4)
Week 1657.5 (47.1 to 67.9)49.4 (38.9 to 59.9)
Week 2064.2 (53.8 to 74.6)60.7 (50.5 to 70.8)
Week 2465.9 (55.8 to 76.0)66.3 (56.3 to 76.3)
Week 2875.6 (66.3 to 84.9)66.7 (56.8 to 76.6)
Week 3275.3 (65.7 to 85.0)67.1 (56.7 to 77.5)
Week 3675.3 (65.5 to 85.2)73.2 (63.6 to 82.8)
Week 4077.3 (67.9 to 86.8)70.2 (60.5 to 80.0)
Week 4480.6 (71.1 to 90.1)75.9 (66.5 to 85.4)
Week 4879.4 (69.8 to 89.0)72.5 (62.7 to 82.3)
Week 5270.6 (59.8 to 81.4)55.6 (44.7 to 66.4)
Week 5667.6 (56.5 to 78.8)57.3 (46.1 to 68.5)
Week 6062.3 (50.1 to 74.5)62.5 (50.6 to 74.4)
Week 6459.6 (46.9 to 72.4)62.3 (49.2 to 75.3)
Week 6858.5 (45.2 to 71.8)61.2 (47.6 to 74.9)
Week 7261.5 (48.3 to 74.8)62.2 (48.1 to 76.4)
SecondaryPercentage of Participants With Absence of Intraretinal Fluid (IRF) Over Time in Overall ITT Population

The absence of IRF in the study eye (defined as IRF absent or definite outside center subfield only) was assessed by the central reading center using SD-OCT. The percentage of participants with absence of IRF at foveal center are reported. Percentages have been rounded off.

Time frame:
Baseline, Weeks 4, 12, 24, 36, 48, and 72
Reported as:
Number · percentage of participants
Percentage of Participants With Absence of Intraretinal Fluid (IRF) Over Time in Overall ITT Population
percentage of participantsArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Baseline19.622.3
Week 453.947.8
Week 1260.551.1
Week 2469.569.8
Week 3670.471.1
Week 4878.878.2
Week 7271.275.6
SecondaryPercentage of Participants With Absence of Subretinal Fluid (SRF) Over Time in Overall ITT Population

The absence of SRF in the study eye (defined as SRF absent or definite outside center subfield only) was assessed by the central reading center using SD-OCT. The percentage of participants with absence of SRF at the foveal center are reported. Percentages have been rounded off.

Time frame:
Baseline, Weeks 4, 12, 24, 36, 48, and 72
Reported as:
Number · percentage of participants
Percentage of Participants With Absence of Subretinal Fluid (SRF) Over Time in Overall ITT Population
percentage of participantsArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Baseline60.463.8
Week 489.982.2
Week 1298.993.4
Week 2498.896.5
Week 3610096.4
Week 4898.597.4
Week 7298.1100

Adverse events

Collected over Up to Week 72. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Vamikibart + Ranibizumab1/93 (1.1%)22/93 (23.7%)38/93 (40.9%)
Arm B: Ranibizumab2/94 (2.1%)17/94 (18.1%)48/94 (51.1%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Cerebrovascular accidentNervous system disorders3/930/94
Myocardial infarctionCardiac disorders2/930/94
Retinal occlusive vasculitisEye disorders2/930/94
VitritisEye disorders2/930/94
OsteoarthritisMusculoskeletal and connective tissue disorders2/930/94
HypoglycaemiaMetabolism and nutrition disorders0/932/94
Carotid artery stenosisNervous system disorders0/932/94
DyspnoeaRespiratory, thoracic and mediastinal disorders0/932/94
HypotensionVascular disorders1/932/94
Peripheral arterial occlusive diseaseVascular disorders1/932/94
Most frequent other events
Most frequent other events
EventArm A: Vamikibart + RanibizumabArm B: Ranibizumab
Diabetic retinal oedemaEye disorders9/9316/94
COVID-19Infections and infestations9/932/94
HypertensionVascular disorders7/939/94
Conjunctival haemorrhageEye disorders8/938/94
Urinary tract infectionInfections and infestations3/938/94
NasopharyngitisInfections and infestations2/937/94
Diabetes mellitusMetabolism and nutrition disorders4/936/94
CataractEye disorders5/933/94
FallInjury, poisoning and procedural complications1/935/94

Baseline characteristics

ITT population included all randomized participants grouped according to the treatment assigned at randomization.

Age, Continuous
Age, Continuous(years)Arm A: Vamikibart + RanibizumabArm B: RanibizumabTotal
Mean61.7 ± 10.162.1 ± 9.361.9 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Vamikibart + RanibizumabArm B: RanibizumabTotal
Female313970
Male6255117
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Vamikibart + RanibizumabArm B: RanibizumabTotal
Hispanic or Latino61420
Not Hispanic or Latino5656112
Unknown or Not Reported312455
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Vamikibart + RanibizumabArm B: RanibizumabTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American7310
White4560105
More than one race000
Unknown or Not Reported413172
08

Study locations

38 sites
  • Win Retina
    Arcadia, California 91006, United States
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
    Torrance, California 90502, United States
  • Bay Area Retina Associates
    Walnut Creek, California 94598, United States
  • Florida Eye Associates
    Melbourne, Florida 30394-7344, United States
  • Retina Vitreous Associates of Florida
    Tampa, Florida 33617, United States
  • Cumberland Valley Retina Consultants
    Hagerstown, Maryland 21740, United States
  • Deep Blue Retina PLLC
    Southaven, Mississippi 38671, United States
  • Verum Research LLC
    Eugene, Oregon 97401, United States
  • Texas Retina Associates
    Arlington, Texas 76012, United States
  • Retina Consultants of Texas
    Bellaire, Texas 77401, United States
  • Organizacion Medica de Investigacion
    Buenos Aires, C1015ABO, Argentina
  • Centro Oftalmológico Dr. Charles S.A.
    Capital Federal, C1116, Argentina
  • Oftalmos
    Capital Federal, C1120AAN, Argentina
  • Buenos Aires Mácula
    Ciudad Autonoma Buenos Aires, C1061AAE, Argentina
  • Grupo Laser Vision
    Rosario, S2000DLA, Argentina
  • Retina Institute of Ottawa
    Ottawa, Ontario K2B 7E9, Canada
  • Toronto Retina Institute
    Toronto, Ontario M3C 0G9, Canada
  • Institut De L'Oeil Des Laurentides
    Boisbriand, Quebec J7H 0E8, Canada
  • Rambam Medical Center
    Haifa, 3109601, Israel
  • Hadassah MC
    Jerusalem, 9112001, Israel
  • Rabin MC
    Petah Tikva, 4941492, Israel
  • Kaplan Medical Center
    Rehovot, 7660101, Israel
  • Tel Aviv Sourasky MC
    Tel Aviv, 6423906, Israel
  • Niepubliczny Zak?ad Opieki Zdrowotnej PRYZMAT-OKULISTYKA
    Gliwice, 44-100, Poland
  • Centrum Medyczne UNO-MED
    Krakow, 31-070, Poland
  • Centrum Diagnostyki i Mikrochirurgii Oka LENS
    Olsztyn, 10-424, Poland
  • Caminomed
    Tarnowskie Góry, 42-600, Poland
  • Emanuelli Research and Development Center LLC
    Arecibo, 00613, Puerto Rico
  • Pusan National University Hospital
    Busan, 49241, South Korea
  • Yeungnam University Medical Center
    Daegu, 42415, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Kim's Eye Hospital
    Seoul, 07301, South Korea
  • Clinica Universitaria de Navarra
    Pamplona, Navarre 31008, Spain
  • Clinica Universitaria de Navarra
    Madrid, 28027, Spain
  • Gloucestershire Hospitals NHS Foundation Trust
    Gloucestershire, GL1 3NN, United Kingdom
  • Royal Surrey County Hospital
    Guildford, GU2 7XX, United Kingdom
  • Kings College Hospital NHS Foundation Trust
    London, SE5 9RS, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Apr 2024, 28 months.

Results were first posted in Oct 2025, 1 year 5 months after primary completion. A results delay was requested in Apr 2025.

Of 32 industry-sponsored phase 2 interventional studies under Macular Edema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 28 months is above that.

Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 15 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2021
First posted
Dec 9, 2021
StartActual
Dec 17, 2021
Primary completionActual
Apr 17, 2024
CompletionActual
Oct 1, 2024
Results delay requested
Apr 1, 2025
Results first posted
Oct 16, 2025
Last update
Oct 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05151744
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 9, 2021
Start date
Dec 17, 2021
Primary completion
Apr 17, 2024
Completion
Oct 1, 2024
Results posted
Oct 16, 2025
Last update
Oct 16, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vamikibart

Start the discussion